Quantcast
Last updated on April 24, 2014 at 16:01 EDT

Latest Oncolytics Biotech Stories

2013-11-21 08:26:35

--Company Intends to Proceed Into Follow-On Registration Study in This Indication-- TORONTO, Nov. 21, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC, NASDAQ:ONCY) today announced positive top-line data for the endpoints in its double blinded, randomized clinical study examining REOLYSIN in combination with carboplatin and paclitaxel in patients with second-line platinum-refractory, taxane-naïve head and neck cancers (REO 018). Summary...

2013-11-07 08:31:16

CALGARY, Nov. 7, 2013 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the quarter ended September 30, 2013. "In recent months we have reported positive data in our squamous cell and non-squamous cell lung clinical trials both in terms of tumour response and survival," said Dr. Brad Thompson, President and CEO of Oncolytics. "On the strength of this reported data, we...

2013-10-28 08:28:06

CALGARY, Oct. 28, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced a poster presentation containing updated efficacy data from a Phase 2 study examining the use of REOLYSIN(®) in combination with carboplatin and paclitaxel in patients with stage IV non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumors (REO 016) was made at International Association for the Study of Lung Cancer (IASLC). The conference is being held...

2013-10-22 08:31:54

CALGARY, Oct. 22, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that a poster presentation covering progression free survival (PFS) and final tumour response data from its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel (REO 021), is being made today at the AACR-NCI-EORTC International...

2013-10-01 12:31:18

CALGARY, Oct. 1, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that abstracts detailing results from two Phase II studies examining the use of REOLYSIN(®) in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumors (REO 016) and in patients with squamous cell carcinoma of the lung (REO 021), are now available on the International Association for the Study...

2013-09-12 08:30:55

NEW YORK, September 12, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Investors' Reports announced new research reports highlighting Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), Oncolytics Biotech, Inc. (NASDAQ: ONCY), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), Sangamo BioSciences, Inc. (NASDAQ: SGMO), and PDL BioPharma, Inc. (NASDAQ: PDLI). Today's readers may access these reports free of charge -...

2013-09-09 16:24:33

CALGARY, Sept. 9, 2013 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at Baird's 2013 Healthcare Conference on Tuesday September 10(th), 2013 at 8:30 a.m. ET. The conference will take place on September 10(th) and 11(th) in New York, NY at the New York Palace. A live audio link to the Baird webcast presentation will be available at: http://wsw.com/webcast/baird35/ONCY. Dr....

2013-09-09 08:26:34

CALGARY, Sept. 9, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced final tumour response data from its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel (REO 021). The analysis examined percent best overall tumour responses between pre-treatment and up to six treatment cycles. Of 25...

2013-08-13 16:26:57

CALGARY, Aug. 13, 2013 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the 2013 Wedbush PacGrow Life Sciences Management Access Conference on Wednesday August 14(th), 2013 at 10:20 a.m. ET. The conference will take place on August 13(th) and 14(th) in New York, NY at the Le Parker Meridien Hotel. A live audio link to the webcast presentation is available at:...

2013-06-04 08:28:22

CALGARY, June 4, 2013 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the 2013 Jefferies Global Healthcare Conference on Thursday, June 6(th), 2013 at 11:00 a.m. ET. The conference will take place from June 3(rd) to 6(th) in New York, NY. A live audio link to the webcast presentation is available at: http://wsw.com/webcast/jeff77/oncy/ or on the company's website at...